Please login to the form below

Not currently logged in

UK pharma slams new drug evaluation plans

ABPI London offices

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

FDA approves Synergy's constipation drug Trulance

FDA headquarters White OakSet to launch by March this year, analysts say the CIC therapy could see sales of $450m by 2020

BMS won't seek quick okay for Opdivo combo in lung cancer

Bristol-Myers Squibb (BMS) buildingNo longer intends to file for accelerated approval, pushing predicted approval date back to late 2018

Sanofi wins EU approval for new diabetes combination Suliqua

Sanofi receptionEuropean Commission licenses the once-daily version of Lantus and Lyxumia

Allergan plans to file oral uterine fibroid drug in US by year-end

Allergan logoAnalysts predict treatment will reach blockbuster sales as phase III trials meet objectives

Novartis takes biosimilar delay complaint to Supreme Court

Novartis buildingSeeks to overturn US law that requires 180-day launch delay after regulatory approval

Gilead's Hepatitis B therapy Vemlidy granted EU approval

Gilead Sciences buildingTreatment shows similar efficacy to the firm's Viread at one-tenth of dosage

NICE U-turn on Novartis' Afinitor for kidney cancer

Novartis HQSet to back treatment's routine NHS use following offer of discount and new data

Merck's Keytruda muscles further ahead of rivals in lung cancer

Merck and Co - US headquartersGranted accelerated review by FDA for use in combination with chemotherapy

Ready for takeoff?

A new pathway promises expedited approvals for innovative medicines

Latest regulatory appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Excel Communications

Excel Communications is a world class training and development company facilitating tailored, in-house learning events including coaching, workshops and development...

Latest intelligence

Medius Deal Watch
Deal Watch December 2016
Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up...
The Young Dementia Network - much more than a logo
Welcome to the second and final part of my two-part blog....
Patient-centred care innovation in dementia: a conversation with Neil Maiden
Content Marketing Manager Liz Inskip interviews Neil Maiden of City, University of London, about his work developing mobile technology solutions for residential dementia care, and what the challenges facing innovators...